Navigation Links
AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan
Date:2/17/2010

RANCHO CORDOVA, Calif., Feb. 17 /PRNewswire-FirstCall/ -- AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation (Nasdaq: APFC), announced today that it has entered into a business collaboration with Inabata & Co., Ltd. Japan (Inabata).  The purpose of the collaboration is to provide access to the Japanese pharmaceutical market for the various technologies that AFC has developed for successfully manufacturing active pharmaceutical ingredients (APIs).  Through its vast network and history in Japan, the agreement names Inabata as AFC's exclusive agent to represent AFC in the country of Japan.

"We are excited about the collaboration with Inabata.  They have a strong track record of successfully pairing technologies with client needs and know the Japanese marketplace well.  Based on their years of experience, they have the ability to identify Japanese partners that can benefit from the use of AFC technologies.  This collaboration will make a great team," said Aslam Malik, President of AFC.

"We are pleased and honored to enter into a partnership with AMPAC Fine Chemicals," stated Seikou Kuroutsu, General Manager of Inabata & Co., Ltd.  "AFC is renowned throughout the world for their expertise in Simulated Moving Bed Separation (SMB) technology, Energetic Chemistry, HPAPIs, as well as the proven ability to manufacture APIs at commercial scale.  AFC's extensive technologies and expertise will enhance our customers' API development and scale-up efforts."

"AMPAC Fine Chemicals is a leading manufacturer of custom small molecule APIs," stated Joe Carleone, Chief Executive Officer of AMPAC.  "We are looking forward to partnering with Inabata enabling our technical leadership to support production of important drug substances for pharmaceutical customers in Japan."

ABOUT AMPAC FINE CHEMICALS LLC

AFC is a U.S.-based company with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients (API's) and registered intermediates for pharmaceutical and biotechnology customers. Its specially engineered facilities and experienced staff allow AFC to safely produce highly energetic compounds at commercial scale. In addition, AFC's other technology platforms include production of highly potent compounds, continuous processes and industrial-scale chromatographic separation using simulated moving bed chromatography (SMB).

ABOUT AMERICAN PACIFIC CORPORATION

American Pacific Corporation (AMPAC) is a leading custom manufacturer of fine chemicals, specialty chemicals and propulsion products within its focused markets. We supply active pharmaceutical ingredients and advanced intermediates to the pharmaceutical industry. For the aerospace and defense industry we provide specialty chemicals used in solid rocket motors for space launch and military missiles. AMPAC also designs and manufactures liquid propulsion systems, valves and structures for space and missile defense applications. We produce clean agent chemicals for the fire protection industry, as well as electro-chemical equipment for the water treatment industry. Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about us can be obtained by visiting our web site at www.apfc.com.

ABOUT INABATA & CO., LTD.

Inabata & Co., Ltd is a Japanese trading company with innovative solutions and services for information technology, electronics, chemicals, plastics, housing materials and food enterprises worldwide.

The Chemicals Division of Inabata provides quality products and information in a timely fashion in order to meet the needs of our customers, taking advantage of its advanced expertise in performance chemicals and life science as well as its global networks.  With unrivalled speed and in close partnership, we hope to be a partner who can offer "time and space outsourcing services" for customers, assisting them in putting their management resources to efficient use. The Chemicals Division responds to broad-ranging needs, including production and logistics services.

Tapping into the wealth of achievements and experience accumulated since our foundation, we are taking the lead in performance chemicals and life science businesses as a dynamic developer of new opportunities.

FORWARD-LOOKING STATEMENTS

Statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation statements regarding anticipated benefits and outcomes from the collaboration of Ampac Fine Chemicals LLC with Inabata & Co., Ltd. and statements regarding the anticipated impact of each company's abilities and expertise on future customers.  The inclusion of forward-looking statements should not be regarded as a representation by American Pacific Corporation and its affiliates (collectively, "American Pacific") that any of American Pacific's expectations will be achieved.  Actual results may differ materially from future results or outcomes expressed or implied by forward-looking statements set forth in this press release due to risks, uncertainties and other important factors inherent in American Pacific's business.  Factors that might cause actual results to differ include, but are not limited to, those included in the "Risk Factors" section of the Form 10-Q for the quarter ended December 31, 2009 filed by American Pacific Corporation with the U.S. Securities and Exchange Commission.  Readers of this press release are referred to the filings of American Pacific Corporation with the U.S. Securities and Exchange Commission, including the Form 10-Q for the quarter ended December 31, 2009 and the Form 10-K for the fiscal year ended September 30, 2009, for further discussion of these and other factors that could affect future results. The forward-looking statements contained in this press release are made as of the date hereof and American Pacific assumes no obligation to update for actual results or to update the reasons why actual results could differ materially from those projected in the forward-looking statements, except as required by law.  

SOURCE American Pacific Corporation

RELATED LINKS
http://www.apfc.com

'/>"/>

SOURCE American Pacific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AMPAC Fine Chemicals Receives Prestigious Award at Californias Annual Statewide Environmental Summit
2. New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals
3. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
4. Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
5. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
6. Codexis Expands Pharmaceutical Manufacturing Partnerships
7. VetCentric Announces Partnership With Pfizer Animal Health
8. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
9. AlloSource and Partners Provide Life-Saving Burn Treatment to Haitian Earthquake Survivors
10. CORD:USE Cord Blood Bank Announces Partnership with Memorial Healthcare System
11. US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - ... service medical device development firm, announced today that it ... Toronto -based medical device industrial design and productization ... companies throughout North America with ... device talent spanning the design, engineering, regulatory, and manufacturing ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, 2017 ... Israel . This new business entity, Emosis Ltd, ... dedicated to research and development of novel assays complementing the mother ... when relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... The Wharton School of the University of Pennsylvania is ... made a $10 million gift to establish the Ken Moelis and Julie Taffet ... to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand ...
(Date:3/28/2017)... ... 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes Association ... Test to find out if they are at risk for developing Type 2 diabetes. ... evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., ... invited to the Siemens Healthineers annual customer education symposium, a world-class learning conference ... place from March 27 - 31, 2017 at the Atlanta Marriott Marquis in ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... ... Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced advanced ... These iSAFE products are the most affordable and most advanced medical alert systems on ... GPS Location and two-way calling with the push of a button on a nationwide ...
Breaking Medicine News(10 mins):